Oncodesign Société Anonyme

ENXTPA:ALONC Stock Report

Market Cap: €99.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oncodesign Société Anonyme Past Earnings Performance

Past criteria checks 0/6

Key information

24.8%

Earnings growth rate

59.4%

EPS growth rate

Biotechs Industry Growth30.8%
Revenue growth rate9.6%
Return on equity-54.7%
Net Margin-18.9%
Last Earnings Update30 Jun 2022

Recent past performance updates

Recent updates

Need To Know: The Consensus Just Cut Its Oncodesign Société Anonyme (EPA:ALONC) Estimates For 2022

Apr 16
Need To Know: The Consensus Just Cut Its Oncodesign Société Anonyme (EPA:ALONC) Estimates For 2022

Calculating The Intrinsic Value Of Oncodesign Société Anonyme (EPA:ALONC)

Jun 08
Calculating The Intrinsic Value Of Oncodesign Société Anonyme (EPA:ALONC)

Are Oncodesign Société Anonyme (EPA:ALONC) Investors Paying Above The Intrinsic Value?

Feb 22
Are Oncodesign Société Anonyme (EPA:ALONC) Investors Paying Above The Intrinsic Value?

Revenue & Expenses Breakdown

How Oncodesign Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALONC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2233-6190
31 Mar 2232-3190
31 Dec 21320190
30 Sep 21331180
30 Jun 21382180
31 Mar 21382180
31 Dec 20342180
30 Sep 20362180
30 Jun 20381180
31 Mar 20381180
31 Dec 19392180
30 Sep 19361180
30 Jun 19341180
31 Mar 1931-1170
31 Dec 1828-3170
30 Sep 1825-5160
30 Jun 1824-7150
31 Mar 1823-6140
31 Dec 1722-5130
30 Sep 1723-2110
30 Jun 17181100
31 Mar 1715180
31 Dec 1615170
30 Sep 1614070
30 Jun 1614060
31 Mar 1615160
31 Dec 1515160

Quality Earnings: ALONC is currently unprofitable.

Growing Profit Margin: ALONC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALONC is unprofitable, but has reduced losses over the past 5 years at a rate of 24.8% per year.

Accelerating Growth: Unable to compare ALONC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).


Return on Equity

High ROE: ALONC has a negative Return on Equity (-54.7%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/23 12:28
End of Day Share Price 2022/12/08 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncodesign Société Anonyme is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary WaandersBryan Garnier & Co
Victor FlochBryan Garnier & Co
Fanny MeindreCIC Market Solutions (ESN)